#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	13978	16S	1529	1529	99.93	16S.l15.c17.ctg.1	2383	715.4	0	.	n	.	0	C1450T	SNP	1450	1450	C	1826	1826	T	893	T,C	889,4	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	13978	16S	1529	1529	99.93	16S.l15.c17.ctg.1	2383	715.4	1	SNP	n	C1184T	0	.	.	1184	1184	C	1560	1560	C	859	C,T	858,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23764	23S	2890	2890	99.93	23S.l15.c17.ctg.1	3976	744.2	0	.	n	.	0	T695C	SNP	695	695	T	1192	1192	C	845	C,T,G	842,1,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23764	23S	2890	2890	99.93	23S.l15.c17.ctg.1	3976	744.2	0	.	n	.	0	T1971C	SNP	1971	1971	T	2468	2468	C	882	C,T	881,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23764	23S	2890	2890	99.93	23S.l15.c17.ctg.1	3976	744.2	1	SNP	n	A2045G	0	.	.	2045	2045	A	2542	2542	A	805	A	805	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23764	23S	2890	2890	99.93	23S.l15.c17.ctg.1	3976	744.2	1	SNP	n	C2597T	0	.	.	2597	2597	C	3094	3094	C	840	C,A,T	837,2,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_F_01537c	folP.WHO_F_01537c	1	1	539	1948	folP	852	852	99.88	folP.l15.c4.ctg.1	2069	117.1	0	.	p	.	0	A204V	NONSYN	610	612	GCA	1140	1142	GTA	162;162;159	G;T,C;A	162;161,1;159	.	.
folP.WHO_F_01537c	folP.WHO_F_01537c	1	1	539	1948	folP	852	852	99.88	folP.l15.c4.ctg.1	2069	117.1	1	SNP	p	R228S	0	.	.	682	684	CGC	1212	1214	CGC	169;172;175	C;G;C	169;172;175	folP.WHO_F_01537c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4940	gyrA	2751	2751	99.82	gyrA.l15.c4.ctg.1	3988	154.4	1	SNP	p	S91F	0	.	.	271	273	TCC	868	870	TCC	172;173;171	T;C;C	172;173;170	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4940	gyrA	2751	2751	99.82	gyrA.l15.c4.ctg.1	3988	154.4	1	SNP	p	D95G	0	.	.	283	285	GAC	880	882	GAC	173;177;179	G;A;C	173;177;179	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4940	gyrA	2751	2751	99.82	gyrA.l15.c4.ctg.1	3988	154.4	1	SNP	p	D95N	0	.	.	283	285	GAC	880	882	GAC	173;177;179	G;A;C	173;177;179	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_W_01449	mtrR.WHO_W_01449	1	1	27	1814	mtrR	633	633	99.68	mtrR.l15.c4.ctg.1	1803	125.3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	938	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1511	77.4	0	.	n	.	0	G33.	DEL	33	33	G	601	601	G	144	G	144	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4526	parC	2304	2304	99.74	parC.l15.c4.ctg.1	3487	161.7	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1875	1877	GCA	217;215;217	G,C;C;A	216,1;215;217	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4526	parC	2304	2304	99.74	parC.l15.c4.ctg.1	3487	161.7	0	.	p	.	0	V596I	NONSYN	1786	1788	GTT	2358	2360	ATT	221;222;221	A;T,G,C;T,G	221;219,2,1;220,1	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4526	parC	2304	2304	99.74	parC.l15.c4.ctg.1	3487	161.7	0	.	p	.	0	V646A	NONSYN	1936	1938	GTG	2508	2510	GCG	207;205;205	G,C;C;G,A	206,1;205;204,1	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4526	parC	2304	2304	99.74	parC.l15.c4.ctg.1	3487	161.7	1	SNP	p	D86N	0	.	.	256	258	GAC	828	830	GAC	193;195;199	G;A;C	193;195;199	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4526	parC	2304	2304	99.74	parC.l15.c4.ctg.1	3487	161.7	1	SNP	p	S87W	0	.	.	259	261	AGT	831	833	AGT	197;196;197	A;G,C;T	197;195,1;197	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4526	parC	2304	2304	99.74	parC.l15.c4.ctg.1	3487	161.7	1	SNP	p	S87I	0	.	.	259	261	AGT	831	833	AGT	197;196;197	A;G,C;T	197;195,1;197	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4526	parC	2304	2304	99.74	parC.l15.c4.ctg.1	3487	161.7	1	SNP	p	S87R	0	.	.	259	261	AGT	831	833	AGT	197;196;197	A;G,C;T	197;195,1;197	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4526	parC	2304	2304	99.74	parC.l15.c4.ctg.1	3487	161.7	1	SNP	p	S88P	0	.	.	262	264	TCC	834	836	TCC	197;198;198	T,G;C;C	196,1;198;198	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4048	parE	1986	1986	99.85	parE.l15.c4.ctg.1	3156	159.8	0	.	p	.	0	V89A	NONSYN	265	267	GTC	853	855	GCC	233;234;227	G;C;C	233;234;227	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4048	parE	1986	1986	99.85	parE.l15.c4.ctg.1	3156	159.8	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1816	1818	GGC	209;209;205	G;G;C	208;208;204	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.45.001	penA.45.001	1	1	27	3684	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2913	157.5	1	SNP	p	A311V	0	.	.	931	933	GCA	1511	1513	GCA	214;216;216	G;C;A	214;216;216	penA.45.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.45.001	penA.45.001	1	1	27	3684	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2913	157.5	1	SNP	p	I312M	0	.	.	934	936	ATC	1514	1516	ATC	216;218;221	A;T;C	216;218;221	penA.45.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.45.001	penA.45.001	1	1	27	3684	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2913	157.5	1	SNP	p	V316P	0	.	.	946	948	GTG	1526	1528	GTG	214;214;212	G;T;G,A	214;214;211,1	penA.45.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.45.001	penA.45.001	1	1	27	3684	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2913	157.5	1	SNP	p	V316T	0	.	.	946	948	GTG	1526	1528	GTG	214;214;212	G;T;G,A	214;214;211,1	penA.45.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.45.001	penA.45.001	1	1	27	3684	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2913	157.5	1	SNP	p	T483S	0	.	.	1447	1449	ACC	2027	2029	ACC	225;226;225	A;C,T;C,A	225;225,1;224,1	penA.45.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.45.001	penA.45.001	1	1	27	3684	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2913	157.5	1	SNP	p	A501P	0	.	.	1501	1503	GCG	2081	2083	GCG	223;221;221	G;C;G,C	223;221;220,1	penA.45.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.45.001	penA.45.001	1	1	27	3684	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2913	157.5	1	SNP	p	A501V	0	.	.	1501	1503	GCG	2081	2083	GCG	223;221;221	G;C;G,C	223;221;220,1	penA.45.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.45.001	penA.45.001	1	1	27	3684	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2913	157.5	1	SNP	p	G542S	0	.	.	1624	1626	GGT	2204	2206	GGT	218;220;220	G;G,A;T	218;219,1;220	penA.45.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.45.001	penA.45.001	1	1	27	3684	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2913	157.5	1	SNP	p	G545S	0	.	.	1633	1635	GGC	2213	2215	GGC	212;215;213	G;G,T,C,A;C	212;212,1,1,1;213	penA.45.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.45.001	penA.45.001	1	1	27	3684	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2913	157.5	1	SNP	p	P551S	0	.	.	1651	1653	CCG	2231	2233	CCG	211;213;212	C,T;C;G	209,2;213;212	penA.45.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	539	5150	ponA	2397	2397	99.87	ponA.l15.c4.ctg.1	3584	179.1	0	.	p	.	0	A375T	NONSYN	1123	1125	GCG	1764	1766	ACG	214;211;215	A,G;C;G	212,2;210;214	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2230	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2415	115.3	0	.	p	.	0	S22G	NONSYN	64	66	AGC	704	706	GGC	150;150;150	G;G;C	150;150;150	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2230	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2415	115.3	0	.	p	.	0	M83fs	FSHIFT	247	247	A	886	886	C	151	C	151	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2696	porB1b	1041	1041	96.18	porB1b.l15.c17.ctg.1	1693	197.5	0	.	p	.	0	T89S	NONSYN	265	267	ACC	741	743	AGC	270;268;267	A,T;G;C,T	268,1;267;266,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2696	porB1b	1041	1041	96.18	porB1b.l15.c17.ctg.1	1693	197.5	0	.	p	.	0	.	MULTIPLE	358	359	AA	833	834	CG	213;208	C;G	213;208	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2696	porB1b	1041	1041	96.18	porB1b.l15.c17.ctg.1	1693	197.5	0	.	p	.	0	.	MULTIPLE	361	362	GA	836	838	CAG	209;212;212	C;A;G	209;212;212	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2696	porB1b	1041	1041	96.18	porB1b.l15.c17.ctg.1	1693	197.5	0	.	p	.	0	N122K	NONSYN	364	366	AAC	840	842	AAA	214;215;214	A;A;A,C	214;215;213,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2696	porB1b	1041	1041	96.18	porB1b.l15.c17.ctg.1	1693	197.5	0	.	p	.	0	F131Y	NONSYN	391	393	TTT	867	869	TAT	223;221;219	T;A,T;T,C	223;220,1;218,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2696	porB1b	1041	1041	96.18	porB1b.l15.c17.ctg.1	1693	197.5	0	.	p	.	0	N134E	NONSYN	400	402	AAT	876	878	GAG	218;218;219	G;A;G	218;218;219	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2696	porB1b	1041	1041	96.18	porB1b.l15.c17.ctg.1	1693	197.5	0	.	p	.	0	V135F	NONSYN	403	405	GTG	879	881	TTT	217;218;217	T,C;T;T	215,2;217;217	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2696	porB1b	1041	1041	96.18	porB1b.l15.c17.ctg.1	1693	197.5	0	.	p	.	0	G140K	NONSYN	418	420	GGA	894	896	AAA	220;221;222	A,T;A;A,G,C	219,1;221;220,1,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2696	porB1b	1041	1041	96.18	porB1b.l15.c17.ctg.1	1693	197.5	0	.	p	.	0	K143E	NONSYN	427	429	AAA	903	905	GAA	216;215;219	G;A;A,G	216;215;218,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2696	porB1b	1041	1041	96.18	porB1b.l15.c17.ctg.1	1693	197.5	0	.	p	.	0	V151A	NONSYN	451	453	GTA	927	929	GCA	236;236;237	G;C,G;A,G	236;235,1;236,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2696	porB1b	1041	1041	96.18	porB1b.l15.c17.ctg.1	1693	197.5	0	.	p	.	0	Y212H	NONSYN	634	636	TAT	1110	1112	CAT	246;244;245	C;A;T	246;244;245	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2696	porB1b	1041	1041	96.18	porB1b.l15.c17.ctg.1	1693	197.5	0	.	p	.	0	T213L	NONSYN	637	639	ACA	1113	1115	TTA	245;248;247	T,G,A;T;A	243,1,1;248;247	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2696	porB1b	1041	1041	96.18	porB1b.l15.c17.ctg.1	1693	197.5	0	.	p	.	0	A244V	NONSYN	730	732	GCA	1206	1208	GTA	217;218;216	G,A;T;A,C	216,1;218;215,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2696	porB1b	1041	1041	96.18	porB1b.l15.c17.ctg.1	1693	197.5	0	.	p	.	0	G253Q	NONSYN	757	759	GGA	1233	1235	CAA	189;189;188	C;A;A	189;189;188	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2696	porB1b	1041	1041	96.18	porB1b.l15.c17.ctg.1	1693	197.5	0	.	p	.	0	.	INDELS	760	762	ACA	1237	1241	ATCAA	187;188;183;180;179	A;T;C;A;A	187;188;183;180;179	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2696	porB1b	1041	1041	96.18	porB1b.l15.c17.ctg.1	1693	197.5	0	.	p	.	0	.	MULTIPLE	764	765	GG	1244	1246	AGT	176;174;174	A;G;T	176;174;174	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2696	porB1b	1041	1041	96.18	porB1b.l15.c17.ctg.1	1693	197.5	0	.	p	.	0	A257D	NONSYN	769	771	GCT	1251	1253	GAT	169;170;169	G;A;T	169;170;169	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2696	porB1b	1041	1041	96.18	porB1b.l15.c17.ctg.1	1693	197.5	0	.	p	.	0	V270A	NONSYN	808	810	GTA	1290	1292	GCG	175;174;174	G;C;G	175;174;174	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2696	porB1b	1041	1041	96.18	porB1b.l15.c17.ctg.1	1693	197.5	0	.	p	.	0	D293S	NONSYN	877	879	GAT	1359	1361	AGT	211;213;212	A;G;T	211;213;212	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2696	porB1b	1041	1041	96.18	porB1b.l15.c17.ctg.1	1693	197.5	1	SNP	p	G120K	1	.	.	358	360	AAG	833	835	CGG	213;208;207	C;G;G	213;208;207	porB1b.WHO_M_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2696	porB1b	1041	1041	96.18	porB1b.l15.c17.ctg.1	1693	197.5	1	SNP	p	A121D	1	.	.	361	363	GAC	836	839	CGC	209;212;213	C;G;C	209;212;213	porB1b.WHO_M_02204c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2696	porB1b	1041	1041	96.18	porB1b.l15.c17.ctg.1	1693	197.5	1	SNP	p	D121N	0	.	.	361	363	GAC	836	839	CGC	209;212;213	C;G;C	209;212;213	porB1b.WHO_M_02204c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	9734	rpoB	4179	4179	100.0	rpoB.l15.c17.ctg.1	5499	220.6	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2285	2287	CAT	248;247;247	C;A,G;T,C,G	248;246,1;244,2,1	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_F_02142c	rpsJ.WHO_F_02142c	1	1	27	1454	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1584	114.3	1	SNP	p	V57M	0	.	.	169	171	GTG	775	777	GTG	247;248;252	G;T,G;G	247;247,1;252	rpsJ.WHO_F_02142c:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
